The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.
Adult
Cytomegalovirus Infections
/ blood
Female
Hepatitis C
Humans
Incidence
Kidney
/ virology
Kidney Transplantation
Male
Middle Aged
Postoperative Complications
/ epidemiology
Proportional Hazards Models
Registries
Retrospective Studies
Tissue Donors
Transplant Recipients
United States
/ epidemiology
Cytomegalovirus infection
direct-acting antiviral agents
end-stage kidney disease
hepatitis C
kidney transplantation
real-word experience
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
30
7
2021
Statut:
ppublish
Résumé
Deceased-donor kidney transplantation (KT) from hepatitis C (HCV)-infected donors into HCV-uninfected recipients (HCV D+/R-) could become standard care in the near future. However, HCV viral replication by viral transmission might lead to a higher incidence of cytomegalovirus (CMV) infection in these recipients. A national-registry-based retrospective cohort study was conducted using the Scientific Registry of Transplant Recipients (SRTR) data set. We assessed the incidence of CMV infection in HCV antibody (Ab) negative recipients receiving kidneys from HCV Ab positive (HCVAb D+/R-) and negative (HCVAb D-/R-) donors. The risk of CMV infection was analyzed by Cox regression analysis in a propensity score (PS) matched-cohort of HCVAb D+/R- ( The mean age at baseline was 54 years, 75% were male, and 55% of the patients were African American in PS-matched cohort. Compared to the HCVAb D-/R - patients, recipients with HCVAb D+/R - showed identical probability for the incidence of CMV infection (Hazard Ratio (HR) = 1.00, 95% Confidence Interval (CI): 0.82-1.22). In the sensitivity analysis, compared to the HCVAb D-/R - patients, the HCVAb D+/R - group had a significantly lower risk of CMV infection in the unadjusted analysis (HR = 0.75, 95%CI: 0.65-0.85), while this risk difference disappeared after the adjusted analysis (HR = 0.99, 95%CI: 0.87-1.14). The incidence of CMV infection was similar in recipients who received HCVAb D + and HCVAb D - KT. Further studies are needed to assess this association in KT from HCV nucleic acid positive donors.
Sections du résumé
BACKGROUND
BACKGROUND
Deceased-donor kidney transplantation (KT) from hepatitis C (HCV)-infected donors into HCV-uninfected recipients (HCV D+/R-) could become standard care in the near future. However, HCV viral replication by viral transmission might lead to a higher incidence of cytomegalovirus (CMV) infection in these recipients.
METHODS
METHODS
A national-registry-based retrospective cohort study was conducted using the Scientific Registry of Transplant Recipients (SRTR) data set. We assessed the incidence of CMV infection in HCV antibody (Ab) negative recipients receiving kidneys from HCV Ab positive (HCVAb D+/R-) and negative (HCVAb D-/R-) donors. The risk of CMV infection was analyzed by Cox regression analysis in a propensity score (PS) matched-cohort of HCVAb D+/R- (
RESULTS
RESULTS
The mean age at baseline was 54 years, 75% were male, and 55% of the patients were African American in PS-matched cohort. Compared to the HCVAb D-/R - patients, recipients with HCVAb D+/R - showed identical probability for the incidence of CMV infection (Hazard Ratio (HR) = 1.00, 95% Confidence Interval (CI): 0.82-1.22). In the sensitivity analysis, compared to the HCVAb D-/R - patients, the HCVAb D+/R - group had a significantly lower risk of CMV infection in the unadjusted analysis (HR = 0.75, 95%CI: 0.65-0.85), while this risk difference disappeared after the adjusted analysis (HR = 0.99, 95%CI: 0.87-1.14).
CONCLUSION
CONCLUSIONS
The incidence of CMV infection was similar in recipients who received HCVAb D + and HCVAb D - KT. Further studies are needed to assess this association in KT from HCV nucleic acid positive donors.
Identifiants
pubmed: 33100098
doi: 10.1080/0886022X.2020.1835675
pmc: PMC7594852
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1083-1092Références
Kidney Int. 2004 Jul;66(1):329-37
pubmed: 15200441
J Viral Hepat. 2019 Dec;26(12):1362-1371
pubmed: 31111619
Ann Intern Med. 2018 Apr 17;168(8):533-540
pubmed: 29507971
Transplant Rev (Orlando). 2013 Apr;27(2):50-6
pubmed: 23481320
Clin Infect Dis. 2002 Oct 15;35(8):974-81
pubmed: 12355385
N Engl J Med. 2017 Jun 15;376(24):2394-2395
pubmed: 28459186
Semin Dial. 2019 Mar;32(2):179-186
pubmed: 30475409
Am J Transplant. 2019 Nov;19(11):2969-2970
pubmed: 31448520
Ann Intern Med. 2018 Aug 21;169(4):214-223
pubmed: 29987322
J Am Soc Nephrol. 2019 Oct;30(10):1939-1951
pubmed: 31515244
Hemodial Int. 2018 Apr;22 Suppl 1:S71-S80
pubmed: 29694722
Front Immunol. 2017 May 17;8:566
pubmed: 28567042
Am J Transplant. 2018 Oct;18(10):2496-2505
pubmed: 30075489
Am J Transplant. 2019 Nov;19(11):3058-3070
pubmed: 31207073
Aging (Albany NY). 2019 Jan 27;11(2):724-740
pubmed: 30686790
Am J Transplant. 2002 May;2(5):461-6
pubmed: 12123213
BMC Infect Dis. 2017 Jul 17;17(1):501
pubmed: 28716027
Transplantation. 2012 Apr 15;93(7):723-8
pubmed: 22406819
N Engl J Med. 2015 Jul 23;373(4):303-5
pubmed: 26200976
Transplant Proc. 2018 Jun;50(5):1437-1443
pubmed: 29880367
J Transl Int Med. 2017 Mar 31;5(1):8-17
pubmed: 28680834
Am J Transplant. 2019 Nov;19(11):3046-3057
pubmed: 31306549
Transplantation. 1999 Dec 27;68(12):1879-83
pubmed: 10628768
Ann Intern Med. 2018 Sep 4;169(5):273-281
pubmed: 30083748
Am J Transplant. 2010 May;10(5):1228-37
pubmed: 20353469